PCI 3.06.26

Current Edition

Current Features

Subsection - Neurodegenerative Diseases

From Depression to Deep-Learning: Leveraging iPSC and AI Platforms for Evidence-Based Depression Treatment

Continue reading

Subsection - Oncology

Essential DMPK Strategies for IND Success

Continue reading

Subsection - Cell and Gene Therapy

When the Gene Editing Guide is the Drug

Continue reading

Upcoming Events

CPHI 2027
AI in Drug Discovery
Auto Draft
Auto Draft
Auto Draft
DDL 2026
Biotechnology Show 13.02.26

Advertisement

Advertisement

A&M Stabtest April 26

Advertisement

Biopharma Group – 19th March 2025

Advertisement

Micron View

Advertisement

Bachem skyscraper
Volume 4 Issue 4

CGT CDMO Partnering: More than just Manufacturing

The biotech footprint has been exponentially expanding around the globe and no division has increased more feverishly in recent years than the Cell and Gene Therapy (...
Continue Reading →
news

Blueprint, taking aim at larger drugmakers, becomes a biotech buyer

Lengo's drug targets a mutation in the gene that drives production of a protein called EGFR, which, in turn, can help spur tumor growth. The mutation, found in the ex...
Continue Reading →
news

Moderna, teaming with a startup, wades further into gene editing

Before it rose to prominence as a vaccine maker, Moderna's original ambitions were to use its messenger RNA technology — a way to prompt the body's cells to produce h...
Continue Reading →
news

Atea, Roche change plans for oral COVID-19 drug after trial setback

Atea's fast ascent last year was due to its plan to use a pill originally developed for hepatitis C infections as a treatment for COVID-19. The strategy resonated wit...
Continue Reading →
news

CureVac scraps its first COVID-19 vaccine and pivots to a second

After months sticking with its coronavirus vaccine, CureVac has finally given up. CureVac executives had long argued the shot could still play a role in fighting COV...
Continue Reading →
news

How a busy year for biotech IPOs measures up at the three-quarter mark

Two records set one year ago could fall, as the number of biotech companies going public and the total amount they've raised are each on pace to eclipse 2020's totals...
Continue Reading →
news

Sarepta embarks on late-stage clinical trial of Duchenne gene therapy

Although Pfizer beat Sarepta to start a Phase 3 trial of its gene therapy, the smaller biotech is claiming a milestone in initiating the study in the U.S. as well as ...
Continue Reading →
news

Biotech funder Lightstone raises another $375M for life sciences investing

For the past few years, and especially since the coronavirus pandemic put healthcare in the spotlight, investors have flocked to young biotech companies. Their inter...
Continue Reading →
news

Moderna founder’s next big play in RNA raises $440M

In about a year's time, Moderna went from an ambitious company with unproven technology to one of the world's most highly valued drug developers. Now, Flagship Pionee...
Continue Reading →
news

Hint of benefit in Alzheimer’s drug study fuel stock surge for Swiss biotech

A small clinical trial of a once-failed Alzheimer's drug offered tantalizing but inconclusive hints of benefit, propelling shares in its biotech maker higher by more ...
Continue Reading →

Advertisement

Richter: Wed 23 October 2024, 09:03

Advertisement

Aseptic Tech

Advertisement

Steribar – 12.05.2025

Advertisement

PharmExcel

Advertisement

Polypure hompage

Advertisement

Gen Xpro

Advertisement

Alphinity

Advertisement

Crown Bioscience

Advertisement

Shimadzu

Advertisement

CPC